Kyto Technology & Life Science, Inc. (KBPH) financial statements (2022 and earlier)
Company profile
| Business Address |
13050 PALOMA ROAD LOS ALTOS HILLS, CA 94022 |
| State of Incorp. | DE |
| Fiscal Year End | March 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2021 TTM | 3/31/2021 | 3/31/2020 | 3/31/2019 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 608 | 1,438 | 34 | 94 | ||
| Cash and cash equivalents | 608 | 1,438 | 34 | 94 | ||
| Receivables | 1 | 1 | ||||
| Deferred costs | 294 | |||||
| Total current assets: | 902 | 1,438 | 34 | 95 | ||
| Noncurrent Assets | ||||||
| Long-term investments and receivables | 2,665 | 1,498 | ||||
| Long-term investments | 2,665 | 1,498 | ||||
| Deferred costs | 170 | |||||
| Total noncurrent assets: | 170 | 2,665 | 1,498 | |||
| Other undisclosed assets | 12,157 | 6,821 | ||||
| TOTAL ASSETS: | 13,058 | 8,429 | 2,700 | 1,593 | ||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 193 | 26 | 22 | |||
| Other undisclosed accounts payable and accrued liabilities | 193 | 26 | 22 | |||
| Due to related parties | 51 | 6 | 7 | |||
| Other undisclosed current liabilities | 1,191 | |||||
| Total current liabilities: | 1,436 | 32 | 29 | |||
| Noncurrent Liabilities | ||||||
| Other undisclosed liabilities | 147 | |||||
| Total liabilities: | 147 | 1,436 | 32 | 29 | ||
| Stockholders' equity | ||||||
| Stockholders' equity attributable to parent, including: | 12,912 | 6,993 | 2,668 | 1,564 | ||
| Common stock | 133 | 100 | 58 | 1 | ||
| Additional paid in capital | 44,631 | 39,772 | 35,943 | 31,562 | ||
| Accumulated other comprehensive loss | (32,957) | (33,384) | (32,611) | |||
| Accumulated deficit | (31,975) | |||||
| Other undisclosed stockholders' equity attributable to parent | 123 | 78 | 50 | 2,613 | ||
| Total stockholders' equity: | 12,912 | 6,993 | 2,668 | 1,564 | ||
| TOTAL LIABILITIES AND EQUITY: | 13,058 | 8,429 | 2,700 | 1,593 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2021 TTM | 3/31/2021 | 3/31/2020 | 3/31/2019 | ||
|---|---|---|---|---|---|
| Revenues | 14 | 9 | |||
| Other undisclosed gross profit | (1,113) | (769) | |||
| Gross profit: | (1,113) | (769) | 14 | 9 | |
| Operating expenses | (237) | (769) | (788) | (239) | |
| Other undisclosed operating loss | (769) | ||||
| Operating loss: | (2,118) | (1,538) | (773) | (230) | |
| Nonoperating income (Investment Income, Nonoperating) | 2,095 | 1,196 | |||
| Interest and debt expense | (0) | ||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 1,195 | ||||
| Income (loss) before gain (loss) on sale of properties: | 1,172 | (342) | (773) | (230) | |
| Other undisclosed net income (loss) | (38) | 769 | |||
| Net income (loss) attributable to parent: | 1,134 | 427 | (773) | (230) | |
| Preferred stock dividends and other adjustments | (132) | ||||
| Net income (loss) available to common stockholders, diluted: | 1,002 | 427 | (773) | (230) | |
Comprehensive Income ($ in thousands)
| 12/31/2021 TTM | 3/31/2021 | 3/31/2020 | 3/31/2019 | ||
|---|---|---|---|---|---|
| Net income (loss): | 1,134 | 427 | (773) | (230) | |
| Comprehensive income (loss), net of tax, attributable to parent: | 1,134 | 427 | (773) | (230) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.